Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxal for Glycemic Control in Men with T2DM and Secondary Hypogonadism
NCT01191320Phase 2Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Oct 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enclomiphene in type 2 diabetes mellitus (T2DM) and secondary hypogonadism (HH) (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: Change in Hemoglobin A1c at 3 months. Started Oct 2010; status: completed.
02
Drugs
enclomiphene
03
Conditions
type 2 diabetes mellitus (T2DM)secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT01191320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191320.